Original Research

Improving the Efficiency of Ordering Next Generation Sequencing During New Patient Triage: A Quality Improvement Project


 

Objective

To decrease the time to treatment by streamlining ordering of next generation sequencing (NGS) during new patient triage utilizing a centralized document of indications for testing.

Background

Use of NGS in management of patients with cancer is rapidly expanding. In 2017, over 75% of oncologists reported using NGS to guide treatment decisions (1). NGS testing is also now incorporated into 67% of NCCN guidelines (2). However, due to the wide variety and changing indications for NGS, integrating testing into routine clinical care can be challenging.

Results

A total of 118 new patients were seen at the SLC VA Oncology Clinic between 2020-2021 of which 21 met criteria for NGS testing at time of triage consult, 10 before and 11 after the intervention. Median time from triage to treatment initiation was 30 days (30-33) after the incorporation of the document into clinic workflow compared to 63 days (47-66). Median time from biopsy to NGS results was similar between pre- and post-intervention groups, 28 (25-49) vs 26 days (18.5-26.5).

Conclusion

Our centralized summary of NGS indications is easily updated and accessible to staff. To date, shorter times from triage to treatment have been seen after integrating this document into clinic workflow. As our sample size is small, further evaluation of this trend is required. However, our data suggests that additional improvement may be achieved through incorporating this document into the Pathology department’s workflow.

References

(1) Freedman A et al. Use of NGS sequencing tests to guide cancer treatment: results from a nationally representative survey of oncologists in the United States. JCO Precis Oncol. 2018;2:1-13. (2) Conway J et al. NGS and the clinical oncology workflow: data challenges, proposed solutions and a call to action. JCO Precis Oncol. 2019;3:1-10.

Recommended Reading

Many pandemic-driven changes to cancer clinical trials should remain
Federal Practitioner
Indoor masking needed in almost 70% of U.S. counties: CDC data
Federal Practitioner
Opioid prescribing laws having an impact
Federal Practitioner
FDA may okay COVID booster for vulnerable adults before weekend: Media
Federal Practitioner
Pathology society first to call for nationwide vaccination mandate
Federal Practitioner
CDC officially endorses third dose of mRNA vaccines for immunocompromised
Federal Practitioner
Secretary of Defense Seeks Approval To Make COVID Vaccines Mandatory For DoD Employees
Federal Practitioner
The Delta Factor
Federal Practitioner
Biden vaccine mandate rule could be ready within weeks
Federal Practitioner
Want to see what COVID strain you have? The government says no
Federal Practitioner